unknown
Stage
About
ILC Therapeutics is a UK-based cytokine engineering company that designs and develops engineered "hybrid interferons", a novel class of cytokine therapeutics intended to reduce toxicity and improve efficacy with an initial focus on infectious disease. The company operates a platform for rational design and selection of candidates and seeks co-development and licensing partners for clinical-stage assets.
Explore ILC Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.